Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-08-31
2008-11-04
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S155100, C424S173100, C424S174100, C530S387100, C530S387300, C530S387700, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388800, C435S326000, C435S328000, C435S332000, C435S334000, C435S343000, C435S343100, C435S344000, C435S346000
Reexamination Certificate
active
07445780
ABSTRACT:
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
REFERENCES:
patent: 4355023 (1982-10-01), Ehrlich et al.
patent: 4689299 (1987-08-01), Insel et al.
patent: 4886796 (1989-12-01), Eichner et al.
patent: 4923872 (1990-05-01), Kostlan et al.
patent: 5068223 (1991-11-01), Lipsky et al.
patent: 5100899 (1992-03-01), Calne
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), De Boer et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5874082 (1999-02-01), de Boer
patent: 7288252 (2007-10-01), Chu et al.
patent: 2002/0028178 (2002-03-01), Hanna et al.
patent: 2002/0142358 (2002-10-01), Mikayama et al.
patent: 2003/0059427 (2003-03-01), Force et al.
patent: 0 434 879 (1991-07-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 945 465 (1999-09-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/00092 (1992-01-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/11794 (1993-06-01), None
patent: WO 94/01547 (1994-01-01), None
patent: WO 94/04570 (1994-03-01), None
patent: WO 95/09653 (1995-04-01), None
patent: WO 96 34096 (1996-10-01), None
patent: WO 00/75348 (2000-12-01), None
patent: WO 01/24823 (2001-04-01), None
patent: WO 01/34649 (2001-05-01), None
patent: WO 01/83755 (2001-11-01), None
An, S., and K.A. Knox et al., “Ligation of CD40 Rescues Ramos-Burkitt Lymphoma B Cells From Calcium Ionophore and Antigen Receptor-Triggered Apoptosis by Inhibiting Activation of the Cysteine Protease CPP32/Yama and Cleavage of its Substrate PARP,”FEBS Letters, 1996, pp. 115-122, vol. 386.
Armitage, R.J., et al., “Molecular and Biological Characterization of a Murine Ligand for CD40,”Nature, 1992, pp. 80-82, vol. 357.
Axcrona, K., et al., “Regulation of B Cell Growth and Differentiation Via CD21 and CD40,”Eur. J. Immunol.1996, pp. 2203-2207, vol. 26.
Bajorath, J. et al., “Construction and Analysis of a Detailed Three-Dimensional Model of the Ligand Binding Domain of the Human B Cell Receptor CD40,”Proteins: Structure, Function and Genetics, 1997, pp. 59-70, vol. 27.
Banchereau, J. et al., “Long-Term Human B Cell Lines Dependent on Interleukin-4 and Antibody to CD40,”Science, Jan. 4, 1991, pp. 70-72, vol. 251.
Banchereau et al., “Growing Human B Lymphocytes in the CD40 System,”Nature, 191, pp. 678-679, vol. 353.
Barr, T.A., and A.W. Heath, “Functional Activity of CD40 Antibodies Correlates to the Position of Binding Relative to CD154,”Immunology, 2001, pp. 39-43, vol. 102.
Benoit, N.E. and W.F. Wade, “Increased Inhibition of Proliferation of Human B Cell Lymphomas Following Ligation of CD4- and Either CD19, CD20 CD95 or Surface Immunoglobulin,”Immunopharmacology, 1996, pp. 129-139, vol. 35.
Berzofsky, J.A. and I.J. Berkower, “Immunogenicity and Antigen Structure,”Fundamenal Immunology, 1993, Chapter 8, p. 242, Raven Press, NY.
Chothia, C. and A.M. Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol., 1987, pp. 901-917, vol. 196.
Claassen, J.J. et al., “Mononuclear Cells from Patients with the Hyper-IgE Syndrome Produce Little IgE When They Are Stimulated with Recombinant Human Interleukin-4,”Journal Allergy Clin., Immunol, 1994, pp. 713-721, vol. 88.
Clark, E.A. and J.A. Ledbetter, “Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50,”Proc. Natl. Acad. Sci., 1986, pp. 4494-4498, vol. 83, USA.
Clark et al., “Association Between IL-6 and CD40 Signaling ILO-6 Induces Phosphorylation of CD40 Receptors,”J. Immunol., 1990, pp. 1400-1416, vol. 145, No. 5.
Cosimi, A.B. et al., “Use of Monoclonal Antibodies T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Rental Allografts,”N. Eng. J. Med., Aug. 6, 1981, pp. 308-313, vol. 305, No. 6.
de Boer, M. et al., “Generation of Monoclonal Antibodies to Human Lymphocyte Cell Surface Antigens Using Insect Cells Expressing Recombinant Proteins,”J. Immunol, Meth., 1992, pp. 15-23, vol. 152.
de Boer, M. et al., “Functional Characterization of a Novel Anti-B7 Monoclonal Antibody,”Eur. J. Immunology, 1992, pp. 3071-3075, vol. 22, No. 12.
DeFranco, A.L. et al. “Separate Control of B Lymphocyte Early Activation and Proliferation in Response to Anti-IgM Antibodies,”Journal of Immunology, 1985, pp. 87-94, vol. 135, No. 1.
Dharakul, T. et al., “Immunization with Baculovirus-Expressed Recombinant Rotavirus Proteins VP1, VP4, VP6 and VP7 Induces CD8+T Lymphocytes That Mediate Clearance of Chronic Rotavirus Infection in SCID Mice,”J. Virol., 1991, pp. 5928-5932, vol. 65, No. 11.
DiSanto, J.P. et al. “Generation of Anti-Human CD8B-Specific Antibodies Using Transfectants Expressing Mixed-Species CD8 Heterodimers,”J. Immunol. Methods, 1991, pp. 123-131, vol. 141.
Edgington, S.M., “How Sweet It Is: Selectin-Mediating Drugs,”Biotechnology, 1992, pp. 383-389, vol. 10.
Ellmark, P. et al., “Modulation of the CD40-CD40 Ligand Interaction Using Human Anti-CD40 Single-chain Antibody Fragements Obtained from the n-CoDeR Phage Display Lirary,”Immunology, 2002, pp. 456-463, vol. 106.
Francisco, J.A. et al., “Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14,”Cancer Research, Jun. 15, 2000, pp. 3225-3231, vol. 60.
Freedman, A.S. et al., “B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells,”Journal of Immunology, 1997, pp. 3260-3267, vol. 139, No. 10.
Freeman, G.J. et al., “Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation,”Science, 1993, pp. 909-911, vol. 262.
Freeman, G.J. et al., “B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells,”Journal of Immunology, 1989, pp. 2714-2722, vol. 143, No. 8.
Funakoshi, S. et al., “Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas,”Journal of Immunology, 1996, pp. 93-101, vol. 19, No. 2.
Funakoshi, S., et al., “Inhibition of Human B-Cell Lymphoma Growth by CD450 Stimulation,”Blood, 1994, pp. 2787-2794, vol. 83, No. 10.
Furman, R.R., et al., “Modulation of NK-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells,”Journal of Immunology, 2000, pp. 2200-2206, vol. 164.
Garrone, P. et al., “Fas Ligation Induces Apoptosis of CD40-Activated Human B Lymphocytes,”J. Exp. Med., 1995, pp. 1265-1273, vol. 182.
Garrone, P. et al., “mAb 104, A New Monoclonal Antibody, Recognizes the B7 Antigen That is Expressed On Activated B Cells and HTLV-1 Transformed T Cells”Immunology, 1990, pp. 531-535, vol. 69.
Gascan, H. et al., “Anti-CD40 Monoclonal Antibodies or CD4 T Cell Clones and IL-4 Induce IgG4 and IgE Switching in Purified Human B Cells Via Different Signaling Pathways,”Journal of Immunology, 1991, pp. 8-13, vol. 147, No. 1.
Gauchat J.-F. et al., “Modulation of IL-4 Induced Germline -ERNA Synthesis in Human B Cells By Tumor Necrosis Factor-a, Anto-CD40 Monoclonal Antibodies
Chu Keting
Masuoka Lorianne K.
Alexander Lisa E.
Gambel Phillip
Henry Leslie T.
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Antagonistic anti-CD40 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonistic anti-CD40 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonistic anti-CD40 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4029002